The dysfunction in how Australia and New Zealand approach pharmaceutical reimbursement is not just procedural. It is rooted in how these systems think about themselves and the myths that sustain their authority. For years, debates over these programs have been channelled into technical terrain that the institution controls and comfortably defends. Institutions shield themselves through their own mythology, recasting policy choices as unquestionable truths. Real reform depends on challenging those myths and exposing the political decisions they conceal.
Process as power - how our institutions defend policy decisions by making them untouchable truths
October 30, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies
April 10, 2026 - - Australian Biotech -
Lower official co-payment but patients paying for more unsubsidised medicines
April 10, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 10 April
April 10, 2026 - - Podcast -
Is there any example of another review or inquiry taking this long?
April 10, 2026 - - Latest News -
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 - - Latest News -
A decade of readiness as AVITA medical expands burn response capability
April 9, 2026 - - Australian Biotech -
Moderna names Carolyn Tucek-Szabo to lead Australia and New Zealand operations
April 9, 2026 - - Latest News
